Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How do model-based and data-driven fault detection methods compare for industrial rotating machinery? A technical guide for R&D and IP professionals.
Article | Report Oveporexton is the first orexin receptor agonist targeting narcolepsy type 1. Explore its FDA approval trajectory, mechanism, and competitive market dynamics.
Article | Report Key engineering challenges of building reliable humanoid robots for industrial deployment at scale — from actuator reliability to locomotion control and dexterity.
Article | Report Explore the key differences between physics-based and data-driven modeling for industrial process optimization, including hybrid approaches and when to use each.
Article | Report Tirzepatide's SURPASS-CVOT trial examines GLP-1/GIP dual agonist cardiovascular and renal outcomes in type 2 diabetes. Explore the science, IP landscape, and clinical significance.
Article | Report How do open-source and proprietary LLMs differ for enterprise R&D? Compare customisation, cost, compliance, and performance to make smarter AI deployment decisions.
Article | Report Sparsentan targets both ETA and AT1 receptors for FSGS and IgAN treatment. Explore the dual receptor antagonism mechanism, IP landscape, and clinical signals.
Article | Report IMerge Phase 3 trial: imetelstat achieved 39.8% 8-week transfusion independence vs 15% placebo in lower-risk MDS. Full pipeline analysis and biomarker data.
Article | Report Key design considerations for thermal management in next-generation AI server rack deployments — cooling strategies, power density challenges, and engineering frameworks.
Article | Report How olutasidenib differs from ivosidenib in IDH1-mutated relapsed AML, plus emerging combination strategies with venetoclax and azacitidine.
Article | Report No verified patent or literature data was available to support a sourced article on ToF vs structured light inline metrology. Learn why evidence-based reporting matters.
Article | Report What stops green hydrogen reaching $2/kg? Explore the key engineering, materials, and systems barriers — from electrolyzer efficiency to membrane degradation.
Article | Report Intellia's NTLA-2002 (Lonvo-Z) targets KLKB1 via CRISPR-Cas9 in vivo editing for HAE. Explore the Phase III pipeline, mechanism, and IP landscape.
Article | Report Deucravacitinib's TYK2 inhibitor expansion into PsA, SLE, and IBD: POETYK, PAISLEY trial data, competitive readouts, and what 2026 means for the class.
Article | Report WAAM vs powder bed fusion for large structural parts: compare deposition rates, scalability, cost, and material performance to choose the right AM process.